Table 2.
Demographic and baseline characteristics for completers at randomisation.
| Placebo group | Liraglutide group | P | |
|---|---|---|---|
| mean (range; SEM) | mean (range; SEM) | ||
| n | 20 | 14 | |
| Age, y | 66.6 (50–80; 1.8) | 63.1 (55–70; 1.3) | 0.16 |
| Sex | 15Male/5Female | 6 Male/8 Female | |
| Gender (% female) | 25 | 57 | - |
| Wechsler Memory Scale | 27.2 (0–57; 3.8) | 27.1 (5–44; 3.4) | 0.99 |
| Duration of Alzheimer’s disease (AD), months | 15 (1–41; 2.5) | 29.5 (5–70; 5.8) | 0.015∗ |
| Onset, years | 65.3 (49–77; 1.9) | 60.3 (50–67; 1.4) | 0.054 |
Data are presented as mean range and standard error of the mean (SEM), and p-values were calculated using unpaired t-test. The Wechsler Memory Scale (WMS-IV) score provides a single score of overall cognitive performance; ∗P < 0.05.